Diabetes mellitus, a chronic metabolic disease characterized by different pathological outcomes as a consequence of unsettled hyperglycemia, often accompanied with various complications such as chronic ulcers, represents a major socio-economic health problem. Dipeptidyl peptidase IV or CD26 molecule (DPP IV/CD26), is an omnipresent transmembrane protein with significant involvements in different physiological and pathological processes. It has been recognized as a therapeutic option in the treatment of hyperglycemia, especially in patients suffering from type 2 diabetes, given its capability to regulate the biological activity of incretins, which are major regulators of glucose homeostasis. Furthermore, DPP IV/CD26 has been indicated to be involved in the regulation of inflammatory processes as well as cell proliferation and angiogenesis. New scientific evidence shows that inhibition of DPP IV/CD26 leads to a more efficacious healing of chronic ulcers in diabetic patients as well as in mice models of wounded tissue restoration. However, the role of DPP IV/CD26 in the process of wound healing in hyperglycemia is not entirely known. Our aim was to summarize most important findings on the involvement of DPP IV/CD26 in the regulation of glycemia as well as tissue regeneration and reparation. This work reviews basic biochemical mechanisms and therapeutic possibilities of DPP IV/CD26 inhibition as a good candidate in the therapy of diabetic wound healing.
https://lupinepublishers.com/biomedical-sciences-journal/fulltext/diabetes-dipeptidyl-peptidase-iv-and-wound-healing-from-basic-science-to-therapeutic-possibilities.ID.000147.php
For more Lupine Publishers Open Access Journals Please visit our website: http://www.lupinepublishers.com/
For more Open Access Journal of Biomedical Engineering articles Please Click Here: https://lupinepublishers.com/biomedical-sciences-journal/
No comments:
Post a Comment
Note: only a member of this blog may post a comment.